紫杉醇脂质体联合顺铂治疗晚期非小细胞肺癌的临床观察

CLINICAL OBSERVATION ON PACLITAXEL LIPOSOME COMBINED WITH CISPLATIN IN THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER

目的观察紫杉醇腊质体（力扑素）联合顺铂（DDP）治疗晚期非小细胞肺癌的近期疗效和毒副反应。方法23例晚期非小细胞肺癌患者应用紫杉醇脂质体联合顺铂化疗，紫杉醇质体135mg／m^2，静滴，d1，顺铂25mg／m^2，静滴，d1～d3。21d为1周期，至少2周期评价疗效。结果23例患者中完全缓解（CR）1例，部分缓解（PR）8例，总有效率（RR）为39．1％。初治者中CR1例，PR4例，有效率为55．6％；复治者中PR4例，有效率为28．6％。初治、复治二组比较差异有统计学意义（P〈0．05）。毒副反应主要表现为骨髓抑制，轻度胃肠道反应。结论紫杉醇腊质体联合顺铂治疗晚期非小细胞肺癌近期疗效确切，毒副反应轻，且初治者疗效优于复治者，因而值得研究、推广应用。

Objective To observe the effect and side effect of paclitaxel liposome combined with cisplatin in the treatment of advanced non- small cell lung cancer. Methods 23 patients with advanced non- small cell lung cancer were treated with paclitaxel liposome and cisplarin： paclitaxel 135mg/m^2 iv dl ,cisplatin 25mg/m^2 iv d2 - d3 for 2 cycles （21 days per cycle） at least. Results Of 23 cases, there was 1 case of CR and 8 cases of PR with overall response rate （ORR） of 39.1%. There was 1 case of CR and 4 cases of PR with response rare of 55.6% among the naive patients, and there were 4 cases of PR with response rate of 28.6 %. The difference between the naive patients and pretreated patients was statistical significance, P 〈0.05. Conclusion Paclitaxel liposome combined with cispalin had confirmed effect and less side effect in the treatment of advanced non-small cell lung cancer. Furthermore the effect in the naive patents is better than that in pretreated patients. So it＇s worth studying and using wildly.